Article
[FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2021
Kawashima Naomi
Abstract excerpt
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene represent the most common genetic alteration in acute myeloid leukemia (AML), identified in approximately one third of patients newly diagnosed with AML. FLT3 internal tandem duplication mutations (FLT3-ITD) are associated with increased relapse and inferior overall survival. Multiple inhibitors of FLT3 signaling have been developed in the last few years...
Topics
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Recurrence
- fms-Like Tyrosine Kinase 3